Comparing the current results to its competitors, Bionano Genomics Inc reported Revenue increase in the 2 quarter 2026 by 21.36 % year on year. The sales growth was above Bionano Genomics Inc 's competitors' average revenue growth of 16.06 %, achieved in the same quarter.
Bionano Genomics Inc , slower than the average decrease reported by the company's competitors of -29.1 %. recorded a net loss and most of the company's competitors saw a decline in earnings by -29.1 %
July 5, 2024
In a significant development, Bionano Genomics Inc. (Nasdaq: BNGO) has announced a substantial fundraising initiative of up to $30 million through a registered direct offering, alongside an upfront payment of $10 million. These funds will be supplemented by an additional $20 million, subject to the exercise of clinical milestone-related Series Warrants. This capital infusion is poised to have a transformative impact on Bionano, fueling their ambitious growth strategy in the fast-evolving genomics industry.Bionano s At-The-Market Offering: Navigating Nasdaq Rules:Bionano s decision to raise capital through a registered direct offering, adhering to Nasdaq rules, highlights the company s commitment to sustainab...
June 20, 2024
Certainly, here is an article suitable for CSIMarket.com : Bionano and Revvity s Strategic Software Partnership Set to Revolutionize Newborn Sequencing Research In a move that promises to reshape the landscape of newborn sequencing research, Bionano Genomics (NASDAQ: BNGO) has entered into a strategic software marketing agreement with Revvity Inc. (formerly known as PerkinElmer). This collaboration aims to accelerate scientific breakthroughs and improve outcomes in neonatal health by leveraging advanced genomic technologies. The Agreement DetailsThe agreement will see Bionano s state-of-the-art software integrated into Revvity s already robust newborn sequencing research workflow. This alliance combines Bio...
March 19, 2024
Advancements in Optical Genome Mapping Provide Novel Insights into Prognosis, Tumor Progression, and Chemotherapy Resistance in Hereditary Breast and Ovarian Cancer SyndromeIn a recent study published in the esteemed journal Oncology, Bionano Genomics, Inc. presented groundbreaking findings on the application of optical genome mapping (OGM) in hereditary breast and ovarian cancer (HBOC) syndrome. The study revealed that tumors with higher overall numbers of structural variations (SVs) exhibited an increased prevalence of mutated genes and altered signaling pathways, which have significant implications for prognosis, tumor progression, and chemotherapy resistance. Additionally, the study demonstrated that OGM...
January 24, 2024
The paradigm of prenatal genetic disease testing is in the precipice of an important shift. Bionano Genomics, Inc., a leading pioneer in the field of genomic analysis, recently announced the publication of the second interim report from an ongoing clinical trial, addressing the incorporation of Optical Genome Mapping (OGM) into the process as a standard of care (SOC).Published on January 24, 2024, this milestone report is part of Bionano s broad clinical trial program aimed at evaluating the potential of OGM to challenge the standard care workflows in prenatal genetic disease diagnosis. Bionano is leading the charge towards a future where genomic analysis stands at the forefront of prenatal diagnosis, a shif...
January 11, 2024
In a groundbreaking development, Bionano, a leading genomics company, has announced the publication of a peer-reviewed study that reinforces the importance of Optical Genome Mapping (OGM) as an integral part of the Standard of Care (SOC) in genetic disease testing. This significant achievement brings us one step closer to more accurate diagnoses and personalized treatment options for individuals affected by genetic disorders.The extensive clinical study conducted by Bionano sought to establish the clinical utility and effectiveness of OGM in identifying various genetic abnormalities. The results of the study have been published in a prestigious peer-reviewed journal, solidifying OGM s credibility as a reliab...
December 28, 2023
In a groundbreaking development, Bionano Genomics, Inc. (Nasdaq: BNGO) has announced significant upgrades to its Bionano Solve pipeline and VIA software for optical genome mapping (OGM) data analysis in constitutional genetic disease research. These advancements have the potential to greatly improve the accuracy and efficiency of diagnosing genetic disorders, offering a ray of hope to millions of patients worldwide. Let s delve into the details and assess their impact on the company.Enhanced Sensitivity and Specificity for Structural Variation (SV) Detection:The latest analysis pipeline, Bionano Solve 3.8.1, is set to revolutionize SV detection from OGM data. By enhancing the sensitivity and specificity of v...
Introduction In a groundbreaking achievement, scientists from Revvity Omics (formerly Perkin Elmer Genomics), Leiden University Medical Centre, Bombay Hospital, and UT Dallas have recently published the largest peer-reviewed study to date, showcasing the significant role of optical genome mapping (OGM) in diagnosing facioscapulohumeral muscular dystrophy (FSHD). The study s findings hold immense promise for improving the efficiency and accuracy of FSHD diagnosis, contributing to enhanced patient care and understanding of this debilitating disorder. The Power of Optical Genome Mapping (OGM) OGM is a cutting-edge genetic analysis technique that offers detailed insights into the structure and o...
10x Genomics Inc is a biotechnology company that specializes in providing tools and solutions for genomic research. Their business model revolves around developing innovative technologies and platforms to enable scientists and researchers to gain deeper insights into the structure and function of biological systems. They offer products such as single-cell sequencing and spatial transcriptomics to support various areas of genomics research and accelerate discoveries in fields like cancer research, immunology, and neuroscience.
Twist Bioscience Corporation operates as a biotechnology company that focuses on synthetic DNA manufacturing. Its business model consists of providing customers with custom DNA synthesis, gene libraries, and specialty components. This includes offering a variety of products and services tailored to meet the specific needs of researchers and biotech companies, enabling them to accelerate their development of personalized medicines, agricultural biotechnology, and more.
Seer Inc operates on a business model that combines technology and human expertise to provide advanced analytics and AI solutions for various industries. They offer customized data-driven insights and strategies to help businesses optimize their operations and make informed decisions.
Pacific Biosciences Of California Inc Share Performance
-7.82%
This Quarter
Pacific Biosciences Of California Inc
Profile
Pacific Biosciences of California Inc's business model revolves around the development and commercialization of innovative sequencing systems that enable scientists and researchers to study the complexity of biology. They provide high-resolution genetic analysis solutions, offering a comprehensive platform that includes consumables, systems, and data analysis software to support genomic analysis.
Sources:
Bionano Genomics Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Bionano Genomics Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
